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Abstract
Binge ethanol consumption has widespread negative consequences for global public health. 
Rodent models offer exceptional power to explore the neurobiology underlying and affected by 
binge-like drinking as well as target potential prevention, intervention, and treatment strategies. 
An important characteristic of these models is their ability to consistently produce 
pharmacologically-relevant blood ethanol concentration. This review examines the current 
available rodent models of voluntary, pre-dependent binge-like ethanol consumption and their 
utility in various research strategies. Studies have demonstrated that a diverse array of 
neurotransmitters regulate binge-like drinking, resembling some findings from other drinking 
models. Furthermore, repeated binge-like drinking recruits neuroadaptive mechanisms in 
mesolimbocortical reward circuitry. New opportunities that these models offer in the current 
context of mechanistic research are also discussed.
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Introduction
With a financial burden estimated in excess of $223 billion in the United States alone 
(Bouchery et al., 2011), ethanol abuse has widespread negative consequences for public 
health and has been implicated in 79,000 deaths annually (Stahre et al., 2004). Not all 
excessive ethanol consumption is the same, however, and different forms of aberrant alcohol 
use are associated with different drinking trajectories and negative consequences (Cleveland 
et al., 2013; Gueorguieva et al., 2012; King et al., 2011; Mota et al., 2013). It is therefore 
important to explore the major subtypes of problematic alcohol use and their associated 
mechanisms and consequences.
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One such subtype, binge drinking, is a hazardous, yet common occurrence in the United 
States. The National Institute on Alcohol Abuse and Alcoholism defines binge drinking 
(BD) as a pattern of drinking that brings blood ethanol concentration (BEC) levels to 80 
mg/dL in a short period of ∼2 hours which can typically be achieved after 4 drinks for 
women and 5 drinks for men. This level of ethanol consumption lies in between light or 
social consumption and the extreme levels typically seen in dependent individuals. BD is 
also defined by periodic, rather than continuous drinking and has been associated with 
increased risk of car accidents, sexual assault, personal injury, and ethanol poisoning. 
Moreover, heavy or frequent BD may lead to a loss of control over alcohol consumption, 
and the development of alcohol use disorders (Courtney and Polich, 2009). Whether or not 
BD is associated with a progression towards dependence in the clinical literature is not yet 
clear (Chassin et al., 2002; Courtney and Polich, 2009; Hasin and Beseler, 2009; King et al., 
2011), however the new spectrum of alcohol use disorder diagnosis presented in the DSM-5 
is arguably more inclusive for BD behavior than was previously seen with the DSM-IV TR. 
Nevertheless, one in six adults in the United States reported engaging in BD about 4 times 
per month in 2010, consuming roughly 8 drinks in each binge episode (CDC, 2012). Thus, 
there is a critical need to better understand the neurocircuitry engaged by BD, as well as how 
this neurocircuitry is altered by repeated bouts of BD, for informed progress in the 
treatment, intervention, and prevention of alcohol use disorders.
Although clinical research has provided critical information regarding the risks and 
consequences of BD, human studies cannot meticulously examine the biological and 
chemical underpinnings of BD due to ethical limitations. Rodent models have therefore been 
extremely valuable in efforts to understand the neurobehavioral mechanisms and 
consequences of binge ethanol consumption. In this review, we will first describe the 
available binge-like drinking rodent models and discuss their application in mechanistic 
research, highlighting findings in key neurotransmitter systems. Finally, we will offer 
suggestions for future utility of these models and how they can continue to advance our 
understanding of the neurobehavioral and genetic mechanisms underlying binge ethanol 
consumption.
Rodent models of voluntary binge-like ethanol consumption
The predominant method of assessing ethanol drinking in rodents has been a two-bottle 
choice paradigm wherein the animal concurrently has access to an ethanol-containing 
solution and water. Often employed as a continuous-access model, this design allows the 
researcher to determine preference for the ethanol solution over water as well as total fluid 
intake in the animal's home cage under normal conditions (save for isolated housing). 
Certain mouse and rat genotypes will consume appreciable amounts of ethanol in this 
paradigm (Eriksson, 1970; McClearn and Rodgers, 1959; Wahlsten et al., 2006), however, 
the continuous nature of this drinking paradigm makes it difficult for the researcher to 
determine when peak drinking/BEC occurs. Indeed, a major limitation is that even animals 
demonstrating a significant preference for ethanol over water rarely achieve 
pharmacologically-relevant BECs in this paradigm (≥ 80 mg/dl) (Dole and Gentry, 1984; 
Linseman, 1987).
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Limiting ethanol access to a discrete time period (typically 1-4 hours each day) has been 
found to produce high ethanol intakes in rodents and BECs ≥ 80 mg/dl in as little as 30 
minutes and produce measurable behavioral intoxication (Bell et al., 2006b; Crabbe et al., 
2011; Cronise et al., 2005; Rhodes et al., 2005). As these observations reflect the NIAAA 
definition of binge drinking, a number of these models have been referred to as ‘binge-like 
drinking models.’ Studies in mouse behavioral and quantitative genetics also suggest that 
this binge-like drinking phenotype is not completely analogous to the continuous, 2-bottle 
choice drinking phenotype (Crabbe et al., 2011; Fritz et al., 2014b; Iancu et al., 2013). This 
is an important point to consider as different genetic factors may predispose individuals for 
binge ethanol drinking, specifically.
A wide variety of approaches to modeling voluntary BD in rodents exist, including 
voluntary home cage drinking, operant paradigms, and dependence-induced drinking. In the 
current review, the authors have elected to focus on pre-dependent, voluntary home cage 
consumption paradigms in mice for a number of reasons. First, operant paradigms 
necessitate an appetitive response component, making interpretation of effects on binge-like 
ethanol consumption, specifically, difficult to ascertain. Second, dependence-induced 
models of BD require animals to be repeatedly exposed to stressful ethanol vapor inhalation 
for up to 12-16 hours per day. The authors argue that modeling BD in this manner lacks face 
and construct validity as this chronic vapor exposure, not prior voluntary ethanol 
consumption, is likely responsible for producing the BD phenotype and therefore reflects the 
maintenance of already established dependence. In addition, a protracted history of binge-
like ethanol consumption in a mouse model of BD did not produce well-established 
behavioral markers of ethanol dependence in rodents (Cox et al., 2013), although an 
elevation of ethanol intake was observed. With these considerations, the scope of this review 
is to examine BD as a pre-dependent mechanism of problematic ethanol consumption, itself. 
In addition, the possibility of whether prolonged BD may usher in a transition to 
dependence is discussed.
Drinking-in-the-Dark
Drinking-in-the-Dark (DID) was developed using the highest ethanol-drinking inbred mouse 
strain, C57BL/6J (B6). This drinking paradigm takes advantage of the most active circadian 
period in mice (3 hrs into the dark cycle) by replacing the animal's water bottle with an 
unsweetened, 20% (v/v) ethanol solution for a short period of 2-4 hrs each day. B6 mice will 
typically consume ∼4-6 g/kg of ethanol by the 2nd DID session (i.e. 2 successive days), 
with a significant proportion reaching BECs in excess of 100 mg/dl with repeated exposures 
(Fritz et al., 2014a; Lyons et al., 2008; Rhodes et al., 2005). DID has been validated as a 
binge-like drinking model as mice reach these intoxicating BECs in a short period of time 
(2-4 hrs) and display behavioral markers of intoxication (Fritz et al., 2014a; Linsenbardt et 
al., 2011; Rhodes et al., 2007). Furthermore, B6 mice have been demonstrated to develop 
functional and metabolic tolerance (Fritz et al., 2014a; Linsenbardt et al., 2011) as well as a 
greater propensity for locomotor sensitization to ethanol (Linsenbardt et al., 2011; Tarragón 
et al., 2012) following repeated cycles of DID, perhaps modeling valid markers of protracted 
ethanol abuse. Concerning whether DID produces ethanol dependence, a previous study 
demonstrated that although repeated DID cycles increased later ethanol intake (Cox et al., 
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2013), this prolonged consumption did not produce other dependence-like phenotypes 
typically demonstrated by rodents following ethanol vapor withdrawal (i.e. anxiety-like 
behavior, convulsions, ataxia). The authors concluded that DID is therefore a pre-dependent 
assessment of binge-like ethanol consumption although the elevation of intake with 
prolonged exposure may suggest a transition towards dependence. Future studies are 
encouraged to address this question by further extending the ethanol exposure period. 
Finally, genotype is an important mediator of propensity to engage in DID (Rhodes et al., 
2007), and consistent with anecdotal evidence from the human literature, adolescent B6 
mice consume greater amounts of binge-like ethanol than adults using DID procedures 
(Moore et al., 2010).
There are numerous variations of DID, particularly relating to the schedule of presentation. 
The original version (Rhodes et al., 2005) offers 2-hr ethanol access for 3 days, and a 4-hr 
access period on day 4. This longer access period effectively allows for greater overall 
ethanol intake as mice will roughly double their consumption to doses of ∼8 g/kg. Others 
have adapted the schedule to draw out to ∼14 days or longer, however only 2-hr access is 
used. The interested reader is referred to Thiele et al. (2014) for details on setting up and 
using DID.
DID-Multi-Scheduled Access
DID multi-scheduled-access (DID-MSA) offers 3-4 daily periods of 1-hr limited access to 
two concentrations of ethanol concurrently (15 and 30% v/v; tap water is also freely 
available), spaced 2-3 hrs apart. Daily ethanol intake equivalent to what is reached if the 
ethanol access is continuous has been observed in selectively-bred high alcohol drinking P 
rats (Bell et al., 2006a; Bell et al., 2011) with mean BECs as high as 120 mg/dl after the first 
hour of access (Bell et al., 2006b). It should be noted that continuous 2-bottle choice access 
to 10% ethanol and water was given before the initiation the DID-MSA protocol. Findings 
from gene expression studies suggest that binge-like drinking in this paradigm produces 
significant alterations in protein expression related to cellular structure and function in the 
nucleus accumbens and amygdala (Bell et al., 2006a; McBride et al., 2010). Moreover, P 
rats drinking ethanol in a continuous access paradigm exhibited substantially more protein 
alterations in the amygdala whereas DID-MSA produced more pronounced alterations in the 
nucleus accumbens (Bell et al., 2006a). These findings suggest that this binge-like drinking 
phenotype produced unique, regionally-specific changes in protein expression.
Our lab has also explored the utility of DID-MSA in B6 mice. Using a variation of the 
paradigm, mice were given 3 daily 1-hr access periods, separated by 2 hrs, to a single bottle 
of 20% (v/v) ethanol for 14 days. Towards the end of the experiment, daily ethanol intakes 
were ≥ 8 g/kg and BECs were ≥ 80 mg/dl following the final hour of access (Melón et al., 
2013). Mice that consumed ethanol in this experiment also exhibited significant ataxia on 
the balance beam apparatus. We have also observed similar binge-like ethanol intake in 
adolescent male and female selectively bred high alcohol-preferring (HAP) mice from the 
first replicate of selection (HAP1) using this paradigm (unpublished observations). Thus, 
DID-MSA also has potential as a mouse model of binge ethanol drinking, although further 
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study regarding the appropriateness of the ethanol concentration offered and the duration of 
the rest periods is needed.
Limited access, 2-bottle choice
One of the limitations of the standard DID procedure is that animals only have access to an 
ethanol solution during the test period. This may be an issue for researchers interested in 
ethanol preference or total fluid intake. However, the 2-bottle choice paradigm also appears 
to be sensitive to limited-access procedures. If offered a choice between 10% or 20% (v/v) 
ethanol and water, B6 mice have been shown to consume ∼2-6.5 g/kg of ethanol and reach 
BECs ∼50-90 mg/dl in a 2-4 hr period as well as demonstrate an ethanol preference of 
∼60-80% (Cozzoli et al., 2014c; Ramaker et al., 2014; Rhodes et al., 2007). Thus, although 
concurrent access to water does appear to reduce ethanol intake in a limited access paradigm 
to some degree relative to the standard DID paradigm described above, BECs at the ‘binge’ 
level (≥ 80 mg/dl) can still be observed.
Scheduled High Alcohol Consumption
The scheduled high alcohol consumption (SHAC) paradigm, also developed using the B6 
strain, models binge consumption (∼2 g/kg) in a very short period of time (∼30 min) and 
has been shown to produce intoxicating BECs ≥ 100 mg/dl (Szumlinski et al., 2007a; 
Tanchuck et al., 2011). SHAC produces high ethanol intake by conditioning mice to 
consume fluids on a schedule. The basic procedure restricts fluid access to 4-10 hrs per day 
with only a portion of this period (∼30 min) offering ethanol access. Ethanol is only offered 
during this designated fluid access period every 3 days with each ethanol access period 
constituting one SHAC ‘cycle’. The procedure also utilizes a lower concentration of ethanol 
than typically used in DID (5% v/v versus 10-20% v/v). Similar to DID, female B6 mice 
exhibit behavioral intoxication following ethanol access (Cronise et al., 2005). Although B6 
mice are the most impressive drinkers in this procedure, genetically heterogeneous mice 
(ethanol-induced Withdrawal Seizure-Control mice; WSC) have been shown to reach BECs 
≥ 100 mg/ml following SHAC access (Finn et al., 2005), demonstrating that this model can 
produce binge-like drinking in mouse genotypes other than B6.
Selected Rodent Lines
High Drinking in the Dark (HDID) mice have been selectively bred from the heterogeneous 
HS/Npt mouse stock for high BECs following 4-hr ethanol access in a 2d DID procedure. 
These mice will consume ethanol in a binge-like manner, engaging in large drinking bouts 
(Barkley-Levenson and Crabbe, 2012) and can reach BECs in excess of 120 mg/dl in a 4-hr 
DID session (Crabbe et al., 2014). Rat lines have also been selected for divergent ethanol 
intake in a limited access paradigm. The high and low drinking lines, referred to as HARF 
and LARF (High/Low Alcohol Research Foundation) (Lê et al., 2001), consumed on 
average 1.2 g/kg and 0.6 g/kg of ethanol, respectively in 30 minute sessions. Unfortunately, 
these rat lines are now extinct and no genetic rat model bred specifically for binge-like 
ethanol drinking currently exists.
For researchers specifically interested in genetic predisposition for BD, HDID mice 
currently offer the most appropriate model. However it is worth noting that HAP1 mice have 
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also been observed to demonstrate impressive ethanol consumption via DID, reaching BECs 
∼100 mg/dl, suggesting at least some genetic overlap between high 2-bottle choice and 
binge-like ethanol drinking (Crabbe et al., 2011). Thus, both HDID and HAP mice offer 
powerful tools for researchers interested in phenotypes associated with a genetic propensity 
for binge-like drinking.
Mechanisms of binge-like alcohol consumption
Dopamine
The most thoroughly studied neurotransmitter in drug/ethanol abuse research, dopamine 
(DA), contributes to the reinforcing and rewarding effects of ethanol (Di Chiara, 1999; 
Koob, 1992; Tupala and Tiihonen, 2004). Although, it is important to highlight that apart 
from psychostimulants, more recent research suggests that DA may play a more diminished 
role in drug and ethanol reinforcement than previously thought (Pierce and Kumaresan, 
2006). A well-known hypothesis for ethanol and drug abuse is an underlying hypofunction 
of the dopamine system (Blum et al., 2015), with consumption of these substances 
theoretically reflecting an attempt to normalize or elevate DA signaling. Ethanol 
consumption has been demonstrated to enhance DA release in rodent (Doyon et al., 2003; 
Melendez et al., 2002; Middaugh et al., 2003) and human (Boileau et al., 2003), nucleus 
accumbens, a mesolimbic area with known involvement in substance use/abuse phenotypes. 
This DA response is thought to reflect disinhibition of DA neurons in the VTA by ethanol, 
resulting in an increased DA efflux from neurons projecting to the accumbens (Froehlich 
and Wand, 1996). Systemic administration of DA agonists has been shown to decrease 
ethanol intake in rodents across a variety of genotypes and paradigms (Cohen et al., 1999; 
Dyr et al., 1993; Ng and George, 1994; Silvestre et al., 1996). Furthermore, a link between 
dopamine D2 receptor levels/function and ethanol abuse/dependence has been demonstrated 
in the clinical literature (Volkow et al., 2015; Volkow et al., 1996) and in rodent models 
(Bice et al., 2008; McBride et al., 1993; Ng et al., 1994; Phillips et al., 1998; Thanos et al., 
2005; Thanos et al., 2001); however, whether these alterations reflect predisposing 
phenotypes or neuroadaptation as a consequence of chronic ethanol exposure is unclear.
Binge-like drinking also appears to have a DA component in rodents, although it has been 
surprisingly understudied. An elevation of extracellular DA levels in the nucleus accumbens 
of male B6 mice during SHAC ethanol drinking was observed using in vivo microdialysis 
procedures (Szumlinski et al., 2007a). Pharmacologic inhibition of the DA transporter 
(DAT) via systemic administration of the drug GBR 12909, theoretically increasing 
extracellular DA levels, significantly reduced ethanol intake via DID in male B6 mice 
(Kamdar et al., 2007). However, this effect was not ethanol-specific as GBR 12909 also 
reduced sugar water intake, suggesting that global inhibition of the DAT may simply 
influence hedonic processes. Interestingly, GBR 12909 infused directly into the accumbens 
shell of P rats did not influence ethanol intake in a procedure resembling 2-bottle DID 
(Engleman et al., 2000). In an attempt to clarify discrepancies in rodent studies about the 
directionality of the relationship between D2 receptor levels and ethanol consumption, 
Bulwa et al. explored the contribution of the two different D2 receptor isoforms: the long 
DA D2 receptor isoform (D2LR) and the short (D2SR) isoform. Mice lacking (knockout; 
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KO) D2LR, and consequently having more D2SR, consume significantly more ethanol via 
the classic DID procedure (Bulwa et al., 2011). Although the roles of the isoforms in ethanol 
sensitivity is not yet known, functional and behavioral differences associated with these 
receptor subtypes (Bulwa et al., 2011; Fetsko et al., 2003; Smith et al., 2002; Usiello et al., 
2000; Wang et al., 2000) highlight their potential to differentially influence sensitivity to 
ethanol and ultimately, binge-like drinking.
Acute systemic injections of ethanol have been consistently demonstrated to produce DA 
efflux in the nucleus accumbens of rats and mice (Imperato and Di Chiara, 1986; Szumlinski 
et al., 2007a; Yim and Gonzales, 2000; Yim et al., 2000), mirroring what was seen during 
binge-like drinking in SHAC (Szumlinski et al., 2007a). Furthermore, the DA response to 
this acute injection was not influenced by the extent of a binge-like ethanol consumption 
history (Szumlinski et al., 2007a). These findings demonstrate that ethanol exposure does 
not need to be contingent with consumption to elevate extracellular DA, suggesting this 
observation is simply a reflection of ethanol's pharmacological effects. Although GBR 
12909 itself has not been extensively studied, activation of DA receptors via agonists has 
been shown to reduce ethanol intake across a variety of rodent genotypes and paradigms 
(Cohen et al., 1999; Dyr et al., 1993; Ng and George, 1994; Silvestre et al., 1996). However, 
sucrose or saccharin solution intake was also observed to be reduced in a number of these 
studies (Cohen et al., 1999; Dyr et al., 1993; Kamdar et al., 2007). One interpretation is that 
this elevated DA signal may serve as a ‘substitute’ for the DA response sought by drugs/
ethanol or natural rewards and this interpretation is strengthened by the observation that DA 
antagonists can decrease ethanol intake (Dyr et al., 1993; Ng and George, 1994). In other 
words, DA agonists may “replace” the augmented DA signal produced by ethanol or other 
natural rewards, and antagonists may prevent the occurrence of this augmented signal, thus 
offering a possible explanation of why both DA receptor antagonists and agonists have been 
observed to reduce the intake of ethanol and other natural reinforcers. Considering how 
much is known about DA in other alcohol abuse rodent models (Tupala and Tiihonen, 
2004), far more work needs to be conducted with these binge drinking models to determine 
the role of DA signaling in binge ethanol consumption.
Glutamate
Ethanol has been shown to influence pre- and postsynaptic glutamate signaling in the central 
nervous system (Chandler, 2003). An acute exposure to ethanol enhances extracellular 
glutamate levels in the nucleus accumbens (Lominac et al., 2006; Moghaddam and Bolinao, 
1994) and VTA (Xiao et al., 2008), and repeated injections have been shown to increase 
basal glutamate levels (Melendez et al., 2005) as well as sensitize the glutamate response to 
ethanol in the accumbens (Szumlinski et al., 2005) and the central amygdala (Roberto et al., 
2004). A well-known pharmacological effect of ethanol is inhibition of the N-methyl-D-
aspartate (NMDA) receptor (Hoffman et al., 1989) and this system is implicated in 
neuroplasticity associated with ethanol abuse/depenence phenotypes (Chandler, 2003; 
Chandler et al., 1998). Indeed, a body of evidence suggests that protracted ethanol exposure 
produces a compensatory increase in glutamate levels and excitability, effects implicated in 
withdrawal-induced seizures and ethanol-seeking (Bäckström et al., 2004; Chandler et al., 
2006).
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Binge-like ethanol intake has been demonstrated to significantly increase extracellular 
glutamate levels in the nucleus accumbens of male B6 mice during ethanol consumption in a 
SHAC procedure, although this was only observed in mice that had previously consumed 
ethanol over repeated SHAC cycles (Szumlinski et al., 2007a). Therefore, this enhanced 
glutamate response appears to reflect ethanol experience-dependent neuroadaptation. 
Interestingly, the antiepileptic drug levetiracetam, which potently inhibits vesicular release 
of glutamate (Meehan et al., 2011; Meehan et al., 2012), has been shown to increase ethanol 
intake in male B6 mice during a 4-hr DID procedure (Fish et al., 2014). In conjunction with 
the microdialysis data described above, this observation may reflect a compensatory 
increase in ethanol intake to oppose the drug-induced reduction in glutamatergic tone. 
Binge-like ethanol intake has also been demonstrated to alter the number and makeup of 
glutamate receptors. Six cycles of SHAC elevated NR2a and NR2b NMDA receptor subunit 
levels in the accumbens of male B6 mice (Cozzoli et al., 2009). A subsequent experiment 
found a 30 day history of 2-hr DID elevated NR2B and mGluR5 levels in the accumbens 
shell of male B6 mice. Increased expression of mGluR1 was also observed in the accumbens 
shell of ethanol-naive high drinking HDID-1 mice relative to their progenitor stock HS/Npt 
counterparts (Cozzoli et al., 2012), and these findings were recently extended to the central 
nucleus of the amygdala using this 30 day DID approach (Cozzoli et al., 2014a).
Pharmacological studies have begun to elucidate the role of specific glutamate receptors in 
binge-like drinking. One of a handful of drugs currently approved to treat ethanol use 
disorders, acamprosate acts partly by blocking NMDA/metabotropic glutamate receptor 
(mGluR) signaling, and systemic administration significantly reduced DID ethanol intake in 
male B6 mice (Gupta et al., 2008). Systemic administration of mGluR5 antagonists reduces 
binge-like ethanol intake across multiple paradigms and mouse genotypes (Gupta et al., 
2008; Tanchuck et al., 2011), however, a recent investigation suggests that their efficacy 
may be influenced by age and sex (Cozzoli et al., 2014b). Local infusion of an mGluR5 
antagonist directly into the nucleus accumbens shell has also been shown to mirror this 
effect (Cozzoli et al., 2009). Although mGluR1 antagonism has not emerged a promising 
pharmacotherapy for alcohol consumption, the negative allosteric modulator JNJ-16259685 
was recently shown to reduce the ethanol intake of male B6 mice in DID when infused into 
the accumbens shell (Lum et al., 2014). Furthermore, this drug effect was dependent on the 
scaffolding protein, Homer2, suggesting that mGluR1 and Homer2 interaction is necessary 
for the drug effect. A number of research groups have thoroughly explored the involvement 
of these complex interactions between glutamate receptors and their scaffolding proteins in 
binge-like drinking in mice. The interested reader is referred directly to a number of these 
studies as these interactions are beyond the scope of this review (Cozzoli et al., 2012; 
Cozzoli et al., 2009; Szumlinski et al., 2007b).
The enhanced accumbal glutamate response following repeated cycles of Binge-like 
drinking resembles what has been shown with chronic injection regimens, although no acute 
response to consumption was demonstrated. The observation that repeated SHAC 
consumption may usher in an enhanced glutamate response component associated with 
dependence could indicate repeated binge-like drinking may represent some facets of 
dependence transition, although this possibility must be more thoroughly explored. For 
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example, extending DID ethanol exposure to 10 cycles (40 total ethanol drinking sessions) 
produced no evidence of well-known dependence phenotypes (e.g. handling-induced 
convulsions, anxiety, ataxia) during withdrawal (Cox et al., 2013), although elevated ethanol 
intake was observed. The efficacy of type 1 glutamate receptor (mGluR1 and mGluR5) 
antagonism/inhibition in reducing binge-like drinking aligns with findings via operant 
paradigms (Bäckström et al., 2004; Hodge et al., 2006b; Schroeder et al., 2005) and 
knockout models (Bird et al., 2008) and has also shown regional specificity in the 
accumbens shell (Besheer et al., 2010). Collectively, these findings suggest that 
glutamatergic mechanisms regulate binge levels of ethanol intake in pre-dependent animals 
and protracted consumption can induce neuroplasticity associated with elevated glutamate 
signaling and alterations in receptor composition/number in key mesolimbic regions.
γ-Aminobutyric Acid (GABA)
Ethanol has been shown to act as a positive modulator of GABA signaling (Ariwodola and 
Weiner, 2004; Mihic et al., 1997; Olsen et al., 2007) and in vitro techniques have 
demonstrated that this effect can be both pre- and postsynaptic (Roberto et al., 2003). 
Ethanol facilitates GABA release and pharmacologically interacts with both GABAA and 
GABAB receptors (Kelm et al., 2011; Paul, 2006) and a variety of agonists/antagonists 
influence ethanol intake in rodents across numerous genotypes and paradigms (Kasten and 
Boehm, 2015; Liang et al., 2006; Moore et al., 2007; Smith et al., 1992; Tanchuck et al., 
2011). Drug discrimination studies in rodents suggest a GABAA receptor component in the 
subjective pharmacological effects of ethanol at doses as low as 0.5-1.0 g/kg (Engel et al., 
2001; Hodge et al., 2006a), doses that would be expected to produce translationally-relevant 
BECs. One theory for GABA's role in ethanol use is that ethanol-induced alterations in 
GABA signaling may serve as regulatory processes within the VTA, ultimately influencing 
the activity of DA neurons projecting to other mesolimbic regions such as the accumbens. 
Indeed, GABAA receptor antagonism within the VTA increases accumbal dopamine levels 
(Kalivas et al., 1990) and slows the acquisition of ethanol self-administration (Nowak et al., 
1998). In addition, a single systemic injection of ethanol has been shown to predominately 
potentiate GABAA receptor transmission in DA neurons within the VTA (Melis et al., 
2002). Interestingly, neuroplastic alterations in VTA DA neurons induced by administration 
of a GABAA receptor agonist were not associated with rewarding or reinforcing effects of 
the drug when either systemically or directly administered into the VTA of mice and non-
human primates (Vashchinkina et al., 2012). This suggests that GABAA receptor 
transmission within the VTA is indeed involved in ethanol consumption and ethanol-
induced neuroplasticity, although its association with ethanol self-administration is complex 
as it is not independently responsible for ethanol's rewarding/reinforcing effects.
Binge-like drinking in mice has also been shown to alter the responsivity of GABA 
signaling as a consequence of voluntarily consumed ethanol. The Szumlinski et al. 
microdialysis study (2007a) found that although the initial voluntary ethanol exposure for 
male B6 mice produced an increase in extracellular GABA in the accumbens, a repeated 
consumption history was associated with no such effect. Another group recently observed 
that a history of binge-like drinking via DID reduced the baseline frequency of GABAA-
receptor mediated inhibitory postsynaptic currents in medium spiny neurons located in the 
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dorsal striatum, evidence of a reduction in presynaptic GABA release (Wilcox et al., 2014). 
Furthermore, acute ethanol-induced GABA responses in these medium spiny neurons in 
water-exposed mice were not observed in mice with a DID history. These observations 
suggest that repeated voluntary binge-like drinking produces reductions in the GABA 
response to ethanol, perhaps indicating a mechanism of neurochemical tolerance.
Ethanol intake in binge-like drinking models is influenced by both ionotropic GABAA and 
metabotropic GABAB receptors. Systemic administration of GABAA receptor agonists has 
been repeatedly shown to decrease ethanol intake and associated BECs in DID paradigms 
(Melón and Boehm II, 2011; Moore et al., 2007; Ramaker et al., 2011; Ramaker et al., 
2012). Local infusion of Ro 15-4513 (a GABAA receptor inverse agonist) into the posterior, 
but not anterior VTA, produced an ethanol-specific decrease in consumption in DID and 
associated BECs (Melón and Boehm II, 2011). This is noteworthy as these anatomical 
subdivisions of the VTA differ in their efferent projections to regions of mesolimbocortical 
circuitry. For example, most DA neuron projections to the medial prefrontal cortex and 
ventromedial striatum arise from the posterior VTA, whereas the anterior VTA prominently 
sends projections to the dorsal striatum and more lateral regions of the nucleus accumbens 
(Ikemoto, 2007; Oades and Halliday, 1987). With respect to ethanol's pharmacological 
effects, ethanol-preferring P rats will self-administer ethanol directly into the posterior, but 
not anterior VTA (Rodd-Henricks et al., 2000). This is particularly interesting in regard to 
the aforementioned hypothesis that a pharmacological component of ethanol reward/
reinforcement may be GABAergic disinhibition of VTA DA neurons. A prominent 
projection target of the VTA, the nucleus accumbens shell also regulates 2-bottle DID 
ethanol intake though GABAA processes as local infusion of the GABAA receptor partial 
agonist THIP significantly reduced ethanol consumption (Ramaker et al., 2014). Finally, 
THIP infused into the infralimbic cortex, a region associated with behavioral flexibility and 
fear extinction (Morgan and LeDoux, 1995; Ragozzino et al., 1999), has been shown to 
promote ethanol intake in DID and associated BECs (Fritz and Boehm II, 2014).
In a version of the SHAC procedure, the GABAB receptor agonist baclofen dose-
dependently reduced ethanol intake in genetically heterogeneous male WSC mice 
(Tanchuck et al., 2011), and our group observed an inverted-U-shaped effect of systemic 
baclofen on ethanol consumption in a 1-hr DID procedure in male B6 mice (Moore et al., 
2007). Recently, we have also shown that that the two different enantiomers of baclofen 
(S(-)- and R(+)) can bidirectionally alter DID ethanol intake with the far more potent R(+) 
enantiomer decreasing ethanol intake, and the less potent S(-)-enantiomer increases intake 
(Kasten and Boehm, 2015). It is unclear whether many previous systemic baclofen studies 
involved the racemate, or one of the individual R(+)-or S(-)- enantiomers as these 
distinctions were typically not made in the literature. In light of these findings, these 
enantioselective effects should be considered. The GABAB receptor positive allosteric 
modulator GS39783 was also found to significantly reduce ethanol intake in the first 15 
minutes (where male B6 mice frontloaded over 40% of their total ethanol intake) of 2-hr 
DID (Linsenbardt and Boehm, 2014). Finally, local infusion of baclofen into the anterior, 
but not posterior VTA was also found to reduce ethanol intake in DID (Moore and Boehm 
II, 2009), and the aforementioned enantioselective effects of baclofen on DID ethanol 
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intake, with R(+) decreasing and S(-)- enhancing intake, were extended to the accumbens 
shell (Kasten and Boehm II, 2014).
Collectively, these findings suggest that acute binge ethanol intake/exposure can induce an 
acute increase in GABA signaling in the accumbens shell and striatum, however repeated 
voluntary exposure blunts these responses, perhaps indicating forms of neurochemical 
tolerance. Furthermore, pharmacological manipulation of both GABAA and GABAB 
receptors significantly influences binge-like drinking as seen with other drinking paradigms, 
although the direction of this effect appears dependent on the influence of particular 
mesocorticolimbic regions, and in the case of baclofen, on the specific enantiomer studied. 
Given ethanol's demonstrated role as a positive modulator of GABA receptor signaling, the 
extent to which GABA receptor manipulation in these key brain regions ‘substitutes’ for or 
interferes with the pharmacological effects of Binge-like ethanol intake should be further 
explored.
Nicotinic Acetylcholine System
The strong association between nicotine and alcohol use/abuse (Funk et al., 2006) has 
prompted researchers to explore the role of the nicotinic acetylcholine receptor (nAchR) in 
alcohol abuse and related neurocircuitry. The clinical literature suggests extraordinarily high 
rates of nicotine dependence in alcohol dependent subjects (Batel et al., 1995) and that the 
amount of alcohol and tobacco individuals consume are positively related (Barrett et al., 
2006). Parallels have been observed in the animal literature. For example, a recent mouse 
study found that when nicotine was infused into the cholinergic-rich basal forebrain of male 
B6 mice, ethanol intake and BECs were increased ∼40% in a standard DID paradigm 
(Sharma et al., 2014). An acute administration of ethanol can influence acetylcholine release 
in the PFC and hippocampus with lower doses increasing and higher doses inhibiting release 
(Henn et al., 1998; Stancampiano et al., 2004). Ethanol has also been shown to 
pharmacologically interact with nicotinic acetylcholine receptors (nAchRs), namely 
inhibiting homomeric α7 receptors and augmenting the activity of the α4β2 receptors (Davis 
and de Fiebre, 2006). A now well-known smoking cessation aid, varenicline, is a partial 
antagonist at α4β2 receptors and has been shown to reduce ethanol consumption in rats and 
mice (Hendrickson et al., 2010; Steensland et al., 2007), with some evidence of a similar 
effect in the clinical literature (McKee et al., 2009). One hypothesis for the high incidence of 
nicotine-ethanol co-abuse is that nicotine may enhance the effects of ethanol. Indeed, drug 
discrimination studies have shown that nicotine can increase the salience of low dose (0.5 
g/kg) ethanol in B6 mice (Ford et al., 2012). Furthermore, nAch receptor activation may be a 
mechanism by which ethanol increases DA efflux in the accumbens (Ericson et al., 2008) 
and combined nicotine/ethanol have been shown to increase VTA DA neuron activity in an 
additive manner (Clark and Little, 2004). Indeed, an acute combined ethanol/nicotine 
injection produced additive locomotor stimulation in mice (Gubner et al., 2013), an effect 
associated with mesolimbic DA stimulation (Pijnenburg et al., 1976).
Pharmacological studies have explored how the regulation of nAchRs influences binge-like 
ethanol consumption. Systemic administration of the nonselective nAchR antagonist 
mecamylamine reduced saccharin and ethanol intake in 2-bottle DID (Ford et al., 2009). 
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However, Hendrickson et al. (2009) found systemic mecamylamine reduced DID ethanol, 
but not sucrose consumption in male B6 mice and that this effect was associated with 
reduced activaton of VTA DA neurons. Interestingly, systemic administration of nicotine 
and the alkaloids cytisine and lobeline, all with agonist properties at these receptors, reduced 
DID ethanol consumption (Hendrickson et al., 2010; Sajja and Rahman, 2011). These 
apparently disparate findings were interpreted as the ability of these agonists to mimic 
components of ethanol's effects on cholinergic signaling within the mesocorticolimbic 
pathway. Systemic varenicline also significantly reduced DID ethanol intake, an effect 
clearly mediated by the α4 subunit (Hendrickson et al., 2010). Furthermore, this effect was 
mirrored via local infusion of varenicline into the posterior, but not anterior VTA. Finally, 
Powers et al. (2013) found that greater ethanol intake via DID was associated with increased 
VTA DA neuron excitability in a genetic mouse model containing supersensitive α6 nAchR 
subunits.
These findings suggest that activation of DAergic neurons in the VTA via acetylcholine has 
the capacity to influence binge-like ethanol consumption and that the α4 subunit appears to 
play a particularly important role. Furthermore, nAchRs located in the basal forebrain also 
directly influence binge-like ethanol intake. Considering the additive potential of nicotine 
and ethanol to increase DA signaling in mesolimbocortical circuitry, an ample opportunity 
for microdialysis and/or electrophysiological experiments exists to explore additive 
neurochemical responses to binge co-consumption of nicotine and ethanol. An operant rat 
model of oral nicotine and ethanol co-consumption has been developed wherein P rats 
consume what could be considered binge levels of both compounds in a short period of 1 hr 
(Hauser et al., 2012).
Endogenous Opioid System
Ethanol has been demonstrated to increase the activity of the endogenous opioid system 
(Froehlich and Li, 1994). Within mesolimbocortical circuitry, ethanol's promotion of opioid 
receptor signaling has been hypothesized to inhibit GABA neurons located within the VTA, 
ultimately producing disinhibition of VTA DA neurons and increased DA release in the 
accumbens (Froehlich and Wand, 1996). Preclinical studies provide some evidence for this 
theory (Xiao et al., 2007) and a recent report demonstrated that although opioid receptor 
antagonists directly administered into the VTA did not prevent ethanol-induced DA efflux in 
the accumbens, it did reduce the duration of this effect (Valenta et al., 2013). There is also a 
translational connection between opioid signaling and ethanol abuse as the non-specific 
opioid receptor antagonist naltrexone, one of the few drugs approved to treat alcohol use 
disorders, significantly reduces ethanol intake in a variety of rodent models (O'Malley and 
Froehlich, 2002) and in heavy drinking human subjects (Spanagel and Vengeliene, 2013).
Naltrexone has been shown to reduce binge-like ethanol consumption in WSC male and 
female mice in a SHAC paradigm (Tanchuck et al., 2011) and in male B6 mice in a 2-hr 
DID procedure (Kamdar et al., 2007). Furthermore, a mouse strain exhibiting reduced 
expression and function of μ-opioid receptors (MORs) readily drinks ethanol in the standard 
DID paradigm and exhibits slightly reduced sensitivity to naltrexone-induced reductions in 
ethanol intake (Tarragón et al., 2012). These results suggest that the MOR may play a role in 
Fritz and Boehm Page 12
Prog Neuropsychopharmacol Biol Psychiatry. Author manuscript; available in PMC 2017 February 04.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
binge-like alcohol consumption in mice, however the degree to which it influences binge 
ethanol intake, specifically, is not clear. Investigation of other opioid receptor subtypes has 
revealed an influential role for the δ subtype (DOR) as DOR KO mice demonstrate 
significantly greater binge-like ethanol intake relative to wildtype mice in 2-bottle DID (van 
Rijn and Whistler, 2009). Further exploration into the involvement of specific DOR receptor 
subtypes found that DOR1 activation reduces binge-like ethanol intake whereas DOR2 
activation may promote consumption (van Rijn et al., 2010; van Rijn and Whistler, 2009).
Collectively, this work suggests that signaling through both MOR and DOR1, specifically, 
appear to be influential regulators of binge-like ethanol intake. The MOR has been shown to 
play an important role in ethanol consumption in other rodent drinking models (Hall et al., 
2001; Lasek et al., 2007; Myers and Robinson, 1999; Roberts et al., 2000) with findings 
generally suggesting that MOR activation is highly important in the reinforcing and 
rewarding properties of ethanol. The findings of the one study addressing this question in a 
BD model (Tarragón et al., 2012) appear somewhat discordant with this body of literature, 
however it should be noted that the mice used in this study were an inbred cross of a B6 
variant and BALB/cByJ and just happen to have a hypofunctioning MOR system. Therefore, 
more direct manipulation of MOR involvement in binge-like drinking is needed to clarify 
this relationship. DOR signaling has also been implicated in other models of ethanol self-
administration as DOR KO mice will consume more ethanol in operant and 2-bottle choice 
paradigms with prolonged exposure (Roberts et al., 2001), however some pharmacological 
studies with non-selective DOR antagonists showed a decrease in intake (Franck et al., 
1998; Froehlich et al., 1991). This highlights the importance of distinguishing between the 
DOR subtypes to explore their unique contributions as has been done by Van Rijn and 
colleagues (2009; 2010) whose work suggests that DOR2 may serve a promotional whereas 
DOR1 serves an inhibitory role in binge-like drinking. Finally, the involvement of the κ-
opioid receptor (KOR) KOR in ethanol reward (Logrip et al., 2009) and 2-bottle choice 
drinking (Kovacs et al., 2005) has also been demonstrated, and this system has been 
implicated in chronic drinking or dependence models, having complex interactions with 
stress (Hölter et al., 2000; Sperling et al., 2010; Walker and Koob, 2008). However, the 
influence of the KOR in BD models is not known.
Corticotropin-releasing factor (CRF)
The involvement of CRF in stress responses has been known for some time. Indeed, 
activation of this system has been associated with increased ethanol responsivity and various 
aspects of the withdrawal state (Heilig and Koob, 2007). In addition, CRF receptor 
antagonists can selectively decrease ethanol intake in dependent, but not non-dependent 
animals, suggesting that this system is recruited in the transition to dependence (e.g. Funk et 
al., 2007). Acute ethanol exposure, however, increases the activity of CRF within 
hypothalamic neurons and can activate the hypothalamic-pituitary-adrenal axis (Li et al., 
2005; Rivier and Lee, 1996). In addition, ethanol acts upon the CRF system to enhance 
GABAergic transmission in the central nucleus of the amygdala (CeA) of non-dependent 
animals (Nie et al., 2004), suggesting ethanol's effects on CRF signaling modify 
transmission in mesolimbocortical reward circuitry prior to the development of dependence.
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A role for CRF in binge-like ethanol intake has been identified. CRF and CRF-1 KO mice 
demonstrate significantly reduced standard and 2-bottle DID ethanol consumption (Giardino 
and Ryabinin, 2013; Kaur et al., 2012). Pharmacological studies have also shown that 
CRF-1 receptor antagonism reduces standard and 2-bottle DID ethanol intake (Giardino and 
Ryabinin, 2013; Sparta et al., 2008), although Giardino and Ryabinin (2013) found that 
these effects were likely due to a non-specific effect on fluid intake, suggesting that 
methodological differences between DID paradigms may elicit different drug effects. 
Lowery and colleagues (2010) explored the role of central CRF receptors and found that 
intracerebroventricular infusion of a nonselective CRF receptor antagonist as well as a 
selective CRF-2 receptor agonist significantly reduced ethanol intake and BEC in a 4-hr 
DID procedure. Microinjections of a CRF-1 receptor antagonists directly into the CeA and 
VTA also significantly reduce DID ethanol intake (Lowery et al., 2010; Sparta et al., 2013). 
These observations are associated with an enhanced capacity of CRF to potentiate NMDA 
receptor signaling in the VTA and a reduced capacity for CRF to enhance GABAergic 
signaling in the CeA in mice with prolonged histories of DID ethanol consumption (Lowery-
Gionta et al., 2012; Sparta et al., 2013). Urocortin 1 (Ucn1) is a neuropeptide similar in 
structure to CRF and binds readily to CRF1 and CRF2 receptors. Ryabinin and colleagues 
(2008) explored the role of Ucn1 and CRF within the lateral septum, an area known to be 
innervated by Ucn1-containing neurons, in binge-like ethanol intake. Intra-lateral septum 
Ucn1 was found to specifically reduce ethanol consumption, however CRF infusion reduced 
intake of water as well.
Collectively, this work suggests that repeated voluntary binge ethanol exposure recruits CRF 
mechanisms resembling those seen in dependence or chronic drinking models with both 
central and peripheral administration of CRF antagonists decreasing binge-like ethanol 
intake. This effect was not previously observed in non-dependent animals (Funk et al., 
2007). In addition, binge-like drinking models demonstrated neuroplasticity of CRF 
signaling within mesolimbocortical circuitry related to both GABA and glutamate 
transmission. Finally, some early evidence suggests that Ucn1, also acting on CRF 
receptors, may exhibit a more specific effect than CRF on binge-like ethanol intake. Future 
studies should address the extent to which CRF effects may actually be explained by more 
specific Ucn1 signaling. Together, these observations raise questions about whether repeated 
BD may indeed recruit mechanisms implicated in dependence. Of course, the timeline of 
these potential effects and their relationship to behavioral phenotypes associated with 
dependence must be thoroughly explored.
Neuropeptide Y (NPY)
NPY has grown in interest in preclinical ethanol research due, in part, to its demonstrated 
effects on anxiety-like (Heilig et al., 1989) and appetitive behavior (Levine and Morley, 
1984) in rodents. Interestingly, its activity appears to oppose that of CRF (Kash and Winder, 
2006; Valdez and Koob, 2004) and NPY levels have been negatively associated with ethanol 
intake and sensitivity (Thiele et al., 1998). Similar to findings with CRF antagonists, central 
NPY administration reduces high alcohol intake of genetically predisposed high drinking 
animals and dependent animals with no effect on the alcohol intake of predisposed low 
drinking or non-dependent animals (Badia-Elder et al., 2003; Badia-Elder et al., 2001; 
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Gilpin et al., 2008). The two most well-known receptor subtypes, Y1 and Y2, appear to 
oppositely influence ethanol intake in rodents with Y1 agonism and Y2 antagonism 
decreasing ethanol intake across multiple rodent genotypes and drinking paradigms (Thiele 
et al., 2002; Thorsell et al., 2002). NPY is thought to reduce ethanol intake primarily 
through the Y1 receptor as these receptors are located postsynaptically, whereas Y2 
receptors are presynaptic autoreceptors, activation of which inhibits endogenous NPY 
release (Sparrow et al., 2012).
Recognizing the association between CRF and NPY and previous observations of DID 
exposure influencing CRF neuroplasticity, the same research group similarly explored 
NPY's role in binge-like ethanol intake. In line with the findings of previous studies, 
Sparrow et al. (2012) found that central administration of NPY, a NPY1 receptor agonist, 
and a NPY2 receptor antagonist all significantly reduced binge-like ethanol intake. They 
also observed that a single 4-day cycle of DID significantly reduced NPY and NPY1 
immunoreactivity in the CeA, and NPY was shown to enhance GABAergic inhibition only 
within the CeA of mice with a repeated DID history. Another recent study showed that 
Y2Rs located specifically on GABA neurons did not influence DID ethanol intake (McCall 
et al., 2013), indicating that the Y2R's effect on binge-like intake must be through a different 
neurotransmitter system.
Together, these results suggest that, similar to dependent or genetic animal models, central 
NPY signaling regulates binge-like drinking. Also in line with previous studies employing 
other drinking models, activation of Y1Rs and inhibition of Y2Rs reduced binge-like 
ethanol intake. Interestingly, NPY pharmacology was previously shown to have no influence 
on ethanol drinking below binge levels in mice (Thiele et al., 2003). Furthermore, the 
negative relationship between NPY levels and consumption (Thiele et al., 1998) was also 
supported as repeated cycles of binge-like drinking reduced NPY and the Y1R. Even so, the 
GABAergic response to NPY is potentiated by a history of binge ethanol consumption, 
perhaps suggesting increased functional properties of the receptor. Collectively, these 
findings corroborate the previously demonstrated link between CRF and NPY in ethanol 
intake and extend them to a model of BD.
Purinergic System
Ethanol is known to positively influence adenosine signaling indirectly via inhibition of its 
transporter, endonucleoside transporter 1, thereby increasing extracellular levels of 
adenosine (Nagy et al., 1990). This effect is thought to be partially responsible for the 
sedative response to ethanol intoxication (Choi et al., 2004), as adenosine signaling 
generally blunts neuronal excitability; an effect that may contribute to the extent of an 
individual's ethanol use. The two main adenosine receptor subtypes, A1 and A2a, have been 
implicated in ethanol-induced ataxia and sedation, respectively (Barwick and Dar, 1998; 
Connole et al., 2004; El Yacoubi et al., 2003; Naassila et al., 2002). Furthermore, the A2a 
receptor has been show to influence ethanol consumption in operant paradigms and 2-bottle 
choice drinking (Adams et al., 2008; Arolfo et al., 2004; Di Bonaventura et al., 2012; 
Thorsell et al., 2007), although the findings are currently equivocal. The authors are unaware 
of any study demonstrating an influence of the A1 receptor on ethanol consumption.
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Recently, our lab added caffeine, a non-selective adenosine receptor antagonist, to the 20% 
ethanol solution in DID at concentrations similar to that found in standard ‘energy drinks.’ 
Although the addition of caffeine had no effect on binge-like ethanol intake or BEC, the 
addition of caffeine significantly interfered with ethanol's depressant motor effects (Fritz et 
al., 2014a). However, caffeine co-consumption had no influence on ethanol-induced 
anxiolysis or memory interference. These results suggest that the motor, but not cognitive 
effects of voluntary binge ethanol intoxication may be more sensitive to adenosinergic 
regulation, a finding consistent with studies employing experimenter-administered caffeine 
and ethanol (López-Cruz et al., 2013). The role of specific adenosine receptor subtypes in 
binge-like drinking and its neurobehavioral consequences has not yet been studied.
Another form of purinergic signaling, P2X receptors are excitatory in nature by binding 
adenosine triphosphate (ATP) to promote cation flux. One particular subtype, P2X4, is 
particularly sensitive to inhibition via ethanol (Davies et al., 2005) and lower expression/
function has been linked to increased ethanol intake and preference (Kimpel et al., 2007; 
Tabakoff et al., 2009). Ivermectin, a widely-known antiparasitic drug, has been shown to be 
a positive allosteric modulator at these receptors. Yardley and colleagues (2012) found that 
systemic administration of ivermectin (10 mg/kg; i.p.) reduced ethanol intake by ∼40% in a 
4-hr DID paradigm. More recently, P2X4 KO mice exhibited increased 2-bottle choice DID 
ethanol intake and although ivermectin reduced their ethanol intake, it was 50% less 
effective than was demonstrated in wildtype mice (Wyatt et al., 2014).
The purinergic system is very diverse and clearly demonstrates sensitivity to binge levels of 
ethanol intake. The findings of these two studies illustrate that binge-like drinking and its 
motor effects are influenced by purinergic signaling, although far more work needs to be 
conducted to determine the role of adensosine receptor subtypes in these behaviors. 
Furthermore, the expression and functional characteristics of these receptors as a 
consequence of voluntary binge ethanol exposure should be addressed.
Other neurotransmitters
A number of studies have also explored the influence of the serotonin (Szumlinski et al., 
2007a), endocannabinoid (Linsenbardt and Boehm II, 2009), ghrelin/leptin (Lyons et al., 
2008), and melanocortin (Olney et al., 2014) systems in binge-like ethanol consumption. 
These findings are not reviewed here as there are relatively little data thus far and the roles 
of these systems in BD models are currently unclear.
Future Directions for the Field
Although our knowledge has clearly advanced substantially in recent years, much work 
remains to better understand the neurobehavioral mechanisms of BD and its consequences. 
Alternative research approaches will be necessary to effectively identify novel 
neurobiological pathways, and to more thoroughly characterize those already identified. A 
number of newer approaches hold much promise in this regard. We review several of them 
below.
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Changes in gene (mRNA) expression are key to both normal and aberrant cellular function. 
Sophisticated molecular and statistical strategies now exist (e.g. microarray analysis) that 
‘cast a wide net’ and allow for the identification of novel functional transcriptional pathways 
to guide future study. Several studies have used such approaches to probe for novel 
functional transcriptional pathways associated with binge-like drinking. In three of these 
studies, nucleus accumbens (Bell et al., 2009; Bell et al., 2006a), VTA (McBride et al., 
2013), and CeA (Bell et al., 2006a) tissue from P rats that had been subjected to a DID-MSA 
procedure were analyzed. The expression of functional groups of genes related to 
neuroinflammation, steroid synthesis/degradation, cellular structure, and ethanol metabolism 
were all identified as being influenced by binge-like drinking. A fourth microarray study 
evaluated gene expression following a single 4-hr DID access period in male B6 mice 
(Mulligan et al., 2011). This group found that genes related to glutamate and serotonin 
signaling as well as blood circulation associated with astrocyte function were positively 
related to the BEC achieved in DID across numerous structures including the frontal cortex, 
striatum, ventral midbrain, hippocampus, cerebellum, and olfactory bulbs. Widespread 
screening of genes in this manner with more genetically heterogeneous animal models (i.e. 
HAP, HDID) may offer a powerful next step in focusing our efforts, especially if an analysis 
of BD duration influence is emphasized.
Molecular-based strategies have also been developed to assess epigenetic regulation of gene 
expression as a consequence of binge ethanol drinking. Focused on how environmental 
factors interact with genetic predispositions to produce a target phenotype, epigenetics is 
highly relevant to the field of substance abuse. One target in the search for epigenetic 
mechanisms associated with binge-like drinking is microRNAs (miRNAs). miRNAs 
expansively regulate downstream transcription of mRNA and are highly responsive to 
environmental factors such as drug or ethanol exposure (Li and van der Vaart, 2011) which 
may ultimately influence neuroplasticity and gene expression. Recently, Nunez and 
colleagues (2013) evaluated miRNA and associated mRNA transcriptional modifications in 
the frontal cortex of high drinking female B6 × FVB/NJ reciprocal cross mice following a 
20 day 2-bottle choice DID procedure. miRNAs were indeed found to regulate transcription 
of target mRNAs with a high degree of consistency (particularly those involved in synaptic 
vesicle trafficking, endocytosis, and neuroimmune signaling). Collectively, the authors 
interpreted these modifications as a reflection of the system's attempt to achieve homeostasis 
in response to the effect of protracted binge ethanol consumption. There is ample 
opportunity for future studies to advance the field by addressing brain region-specific roles 
of miRNAs in the regulation of target proteins/processes as a consequence of various 
durations of voluntary binge ethanol consumption.
Recent ‘state-of-the-art’ in vivo experimental approaches have also been developed to more 
directly assess the intricate relationships between brain and behavior. As mentioned 
previously, current rodent BD models can produce pharmacologically relevant BECs and 
intoxication in a discrete period as short as 30 min. This is a key strength for highly precise 
techniques that require fine temporal resolution of behavior such as in vivo 
electrophysiology or highly-localized selective stimulation/inhibition of specific cell types 
via optogenetics (Aravanis et al., 2007). BD models provide readily definable periods of 
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drinking behavior which coincide well with event mapping in both techniques. Continuous 
access paradigms are simply not practical for such techniques due to both time requirements 
and concerns over pharmacologically relevant intake. Another elegant technique well-suited 
for these models is the designer receptors exclusively activated by designer drugs 
(DREADDS) approach (Lee et al., 2014). DREADDS technology essentially involves viral-
vector mediated transfer of receptors designed to only respond to clozapine-n-oxide (CNO) 
and can be coupled to stimulatory or inhibitory G-proteins. A key advantage of this 
technique is that a simple systemic administration of CNO is all that is needed for the 
precise manipulation within the central nervous system, thereby allowing for a significant 
reduction in the complexity of data collection and analysis. These BD paradigms would be 
expected to produce intoxicating BECs in the discrete period of time where CNO would 
exert its designed pharmacological effect; something that could not be convincingly 
employed in a continuous access model. Therefore, these approaches should be considered 
in future preclinical BD research to explore its mechanistic underpinnings and 
consequences.
Finally, it may be obvious from the literature reviewed above that the current findings are 
largely restricted to a single rodent genotype (B6 mice) and the focus is mainly on male 
animals. Although the inbred B6 mouse strain is clearly the most readily available animal 
that will consume ethanol in a binge-like manner with virtually no training, researchers 
should consider HDID and HAP mice as alternative, and perhaps superior models as they 
also readily consume ethanol in a binge manner. These animals have been selectively bred 
for their respective ethanol consumption phenotypes which theoretically leaves unassociated 
alleles unfixed, making these mice substantially heterogeneous. In addition, it is becoming 
clearer that ethanol abuse is unique and perhaps more rapidly destructive in females 
(Greenfield et al., 2010; Keyes et al., 2010). Researchers should include both male and 
female animals in their experiments, and focused efforts should be made to understand how 
estrous cycle status uniquely alters binge-like intake in females.
In conclusion, the field of preclinical BD research has revealed many exciting 
neurobiological targets for further study. As efforts are focused to advance our 
understanding in the areas mentioned above, it will be important to explore the mechanisms 
of binge-like drinking over varying durations of exposure, offering insight on the 
progression of BD and whether it may lead towards dependence. With the current 
mechanistic/genetic techniques available to researchers today, we encourage the use of these 
convenient and reliable rodent BD models which offer substantial potential to rapidly 
progress our understanding of the biomolecular underpinnings and consequences of BD.
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CNO clozapine-n-oxide
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DREADDS designer receptors exclusively activated by designer drugs
DA dopamine
DAT dopamine transporter
DID Drinking-in-the-Dark
DID-MSA Drinking-in-the-Dark - multi-scheduled-access
GABA γ-aminobutyric acid
HAP high alcohol-preferring mice
HARF High Alcohol Research Foundation rats
HDID High-drinking-in-the-dark mice
KOR κ-opioid receptor
KO knockout
D2LR long dopamine D2 receptor isoform
LARF Low Alcohol Research Foundation rats
miRNAs microRNAs
MOR μ-opioid receptor
nAchR nicotinic acetylcholine receptor
NMDA N-methyl-D-aspartate
MOR μ-opioid receptor
NPY Neuropeptide Y
SHAC scheduled high alcohol consumption
D2LR short dopamine D2 receptor isoform
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